中村 善雄

Medicine & Life Sciences

1. Extramammary Paget's Disease 100%
2. Melanoma 71%
3. Nivolumab 59%
4. Ipilimumab 34%
5. Skin 25%
6. Primary malignant melanoma of the cervix 25%
7. Survival 23%
8. Basal Cell Carcinoma 22%
9. pembrolizumab 21%
10. Linear IgA Bullous Dermatosis 20%
11. Therapeutics 20%
12. Neoplasms 18%
13. Epirubicin 18%
14. Phase II Clinical Trials 17%
15. Squamous Cell Carcinoma 17%
16. TP protocol 17%
17. Keratin-19 16%
18. Combined Vaccines 16%
19. Carboplatin 16%
20. Wilms' Tumor Genes 16%
21. Skin Neoplasms 16%
22. human ERBB2 protein 15%
23. Irinotecan 14%
24. Hydronephrosis 14%
25. Imatinib Mesylate 14%
26. Carcinoembryonic Antigen 13%
27. Docetaxel 13%
28. Oncologists 13%
29. Vagina 13%
30. Hepatectomy 13%
31. Vancomycin 13%
32. Wilms Tumor 12%
33. Adjuvant Chemotherapy 12%
34. Paclitaxel 12%
35. Drug Therapy 12%
36. Lymph Node Excision 12%
37. Tumor Biomarkers 12%
38. taxane 11%
39. Immunoglobulin A 11%
40. Dendritic Cells 11%
41. Anthracyclines 10%
42. Antibodies 10%
43. HLA-A24 Antigen 10%
44. Serum 10%
45. Apoptosis 8%
46. Research Personnel 8%
47. Merkel Cell Carcinoma 8%
48. Fluorescence In Situ Hybridization 8%
49. Retrospective Studies 8%
50. Safety 8%